Effects of Ganopoly® (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients

Immunological Investigations

Volumn 32, Issue 3, 2003, Pages 201-215

  Gao, Yihuai ^d   Zhou, Shufeng ^a   Jiang, Wenqi ^d   Huang, Min ^b   Dai, Xihu ^c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SUN YAT SEN UNIVERSITY   (China)

^c FUZHOU GENERAL HOSPITAL   (China)

^d NONE

Author keywords

Efficacy; Ganoderma lucidum; Polysaccharide; Safety; Tumor

Indexed keywords

ANTINEOPLASTIC AGENT; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GANODERMA LUCIDUM EXTRACT; GANOPOLY; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; PHYTOHEMAGGLUTININ; POLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; HERBACEOUS AGENT;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER STAGING; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; FEMALE; FOLLOW UP; GANODERMA LUCIDUM; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LEUKOCYTE COUNT; LIVER CANCER; LUNG CANCER; LYMPHOCYTE SUBPOPULATION; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; TUMOR IMMUNITY; BLOOD; CELLULAR IMMUNITY; CLINICAL TRIAL; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MIDDLE AGED; NEOPLASM; PHYTOTHERAPY;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CYTOKINES; DRUGS, CHINESE HERBAL; HUMANS; IMMUNITY, CELLULAR; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; MIDDLE AGED; NEOPLASMS; PHYTOTHERAPY; POLYSACCHARIDES; REISHI;

EID: 0041853581     PISSN: 08820139     EISSN: None     Source Type: Journal    
DOI: 10.1081/IMM-120022979     Document Type: Article

References (48)

1. Agarwala, S. S., Glaspy, J., O'Day, S. J., Mitchell, M., Gutheil, J., Whitman, E., Gonzalez, R., Hersh, E., Feun, L., Belt, R., Meyskens, F., Hellstrand, K., Wood, D., Kirkwood, J. M., Gehlsen, K. R., Naredi, P. (2002). Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J. Clin. Oncol. 20:125-133.
2. Argiles, J. M., Lopez-Soriano, F. J. (1999). The role of cytokines in cancer cachexia. Med. Res. Rev. 19:223-248.
3. Battle, J., Ha, T. Z., Li, C. F., Dellabeffa, V., Rice, P., Kalbfleisch, J., Browder, W., Williams, D. (1998). Ligand binding to the (1-3)-beta-D-glucan receptor stimulates NF-kappa B activation, but not apoptosis in U937 cells. Biochem. Biophys. Res. Commun. 249:499-504.
4. Brittenden, J., Heys, S. D., Ross, J., Eremin, O. (1996). Natural killer cells and cancer. Cancer 77:1226-1243.
5. Burnet, F. M. (1971). Immunological surveillance in neoplasia. Transplant. Rev. 7:3-13.
6. Chang, R. (1994). Effective dose of Ganoderma in humans. In: Buchanan, P. K., Hseu, R. S., Moncalvo, J. M., eds. Proc 5th Int Mycol Congr. 5th International Mycology Congress Organizing Committee. pp. 117-121. Vancouver.
7. Chang, R. (1996). The central importance of the beta-glucan receptor as the basis of immunologic bioactivity of Ganoderma polysaccharides. In: Mizuno, T., Kim, B. K., eds. Seoul: II Yang Press, pp. 177-179.
8. Chen, S. (2001). In vitro mechanism of PC-SPES. Urology 58:28-35.
9. Cooper, M. A., Fehniger, T. A., Caligiuri, M. A. (2001). The biology of human natural killer-cell subsets. Trend Immunol. 22:633-640.
10. Czop, J. K., Austen, K. F. (1985). A beta-glucan inhibitable receptor on human monocytes. J. Immunol. 134:2588-2593.
11. Diamond, M. S., Garcia-Aguilar, J., Bickford, J. K., Corbi, A. L., Springer, T. A. (1993). The I domain is a major recognition site on the leukocyte integrin Mac-1 (CD11b/CD18) for four distinct adhesion ligands. J. Cell Biol. 120:1031-1043.
12. Gibbs, J. B. (2000). Mechanism-based target identification and drug discovery in cancer research. Science 287:1969-1973.
13. Goto, S., Sato, M., Kaneko, R., Itoh, M., Sato, S., Takeuchi, S. (1999). Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients. Cancer Immunol. Immunother. 48:435-442.
14. Haslett, P. A. J. (1998). Anticytokine approaches to the treatment of anorexia and cachexia. Semin. Oncol. 25:53-57.
15. Hwang, S. F., Liu, K. J., Kuan, Y. H., Tung, K. S., Su, C. H., Tung, T. C. (1989). The inhibitory effect on artificial pulmonary metastasis of murine S-180 sarcoma cells by orally administered Ganoderma lucidum culture broth. J. Chin. Oncol. Soc. 5:10-15.
16. Jovic, V., Konjevic, G., Radulovic, S., Jelic, S., Spuzic, I. (2001). Impaired perforin-dependent NK cell cytotoxicity and proliferative activity of peripheral blood T cells is associated with metastatic melanoma. Tumori 87:324-329.
17. Kempf, R. A., Mitchell, M. S. (1985). Effects of chemotherapeutic agents on the immune response. II. Cancer Investig. 3:23-33.
18. Kishida, E., Okuda, R., Sone, Y., Misaki, A. (1988). Fractionation structures and antitumor activities of the polysaccharides of Reishi, the fruiting body of Ganoderma lucidum. Osaka Shiritsu Daigaku Seikatsu Kagakubu Kiyo 35:1-10.
19. Konopski, Z., Smedsrod, B., Seljelid, R., Eskeland, T. (1994). A novel immunomodulator soluble aminated β-1,3-D-glucan: binding characteristics to mouse peritoneal macrophages. Biochim. Biophys. Acta, Mol. Cell Res. 1221:61-65.
20. Lauerova, L., Dusek, L., Simickova, M., Kocak, I., Vagundova, M., Zaloudik, J., Kovarik, J. (2002). Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma 49:159-166.
21. Lee, J. O., Rieu, P., Arnaout, M. A., Liddington, R. (1995a). Crystal structure of the A domain from the alpha subunit of integrin CR3 (CD11b/CD18). Cell 80:631-638.
22. Lee, S. S., Wei, Y. H., Chen, C. F., Wang, S. Y., Chen, K. Y. (1995b). Antitumor effects of Ganoderma lucidum. J. Chin. Med. 6:1-12.
23. Liu, X., Yuan, J. P., Chung, C. K., Chen, X. J. (2002). Antitumor activity of the sporoderm-broken germinating spores of Ganoderma lucidum. Cancer Lett. 182:155-161.
24. Mihich, E., Fefer, A. (1983). Biological response modifiers: subcommittee report. NCI Monogr. 63.
25. Miyazaki, T., Nishijima, M. (1981). Studies on fungal polysaccharides. XXVII. Structural examination of a water-soluble, antitumor polysaccharide of Ganoderma lucidum. Chem. Pharm. Bull. 29:3611-3616.
26. Moretta, L., Bottino, C., Pende, D., Mingari, M. C., Biassoni, R., Moretta, A. (2002). Human natural killer cells: their origin, receptors and function. Eur. J. Immunol. 32:1205-1211.
27. Mueller, A., Raptis, J., Rice, P. J., Kalbfleisch, J. H., Stout, R. D., Ensley, H. E., Browder, W., Williams, D. L. (2000). The influence of glucan polymer structure and solution conformation on binding to (1- > 3)-beta-D-glucan receptors in a human monocyte-like cell line. Glycobiology 10:339-346.
28. Muller, A., Rice, P. J., Ensley, H., Coogan, P. S., Kalbfleisch, J. H., Kelley, J. L., Love, E. J., Portera, C. A., Ha, T. Z., Browder, I. W., Williams, D. L. (1996). Receptor binding and internalization of a water-soluble (1-3)-beta-D-glucan biologic response modifier in two monocyte macrophage cell lines. J. Immunol. 156:3418-3425.
29. Paulsen, B. S. (2001). Plant polysaccharides with immunostimulatory activities. Curr. Org. Chem. 5:939-950.
30. Ratain, M. J. (1997). Pharmacology of cancer chemotherapy. In: DeVita, V. T., Hellman, S., Rosenberg, S. A., eds. Philadelphia: Lippincott-Raven Publishers, pp. 375-509.
31. Ratain, M. J., Relling, M. V. (2001). Gazing into a crystal ball - cancer therapy in the post-genomic era. Nat. Med. 7:283-285.
32. Robertson, M. J., Ritz, J. (1990). Biology and clinical relevance of human natural killer cells. Blood 12:2421-2438.
33. Santin, A. D., Hermonat, P. L., Ravaggi, A., Bellone, S., Roman, J., Pecorelli, S., Cannon, M., Parham, G. P. (2000). Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix. Int. J. Radiat. Oncol. Biol. Phys. 48:997-1006.
34. See, D., Mason, S., Roshan, R. (2002). Increased tumor necrosis factor alpha (TNF-alpha) and natural killer cell (NK) function using an integrative approach in late stage cancers. Immunol. Invest. 31:137-153.
35. Small, E. J., Frohlich, M. W., Bok, R., Shinohara, K., Grossfeld, G., Rozenblat, Z., Kelly, W. K., Corry, M., Reese, D. M. (2000). Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J. Clin. Oncol. 18:3595-3603.
36. Sone, Y., Okuda, R., Wada, N., Kishida, E., Misaki, A. (1985). Structural and anti-tumor activities of polysaccharides isolated from fruiting body and the growing culture of mycelium of Ganoderma lucidum. Agr. Biol. Chem. 49:2641-2653.
37. Thornton, B. P., Vetvicka, V., Pitman, M., Goldman, R. C., Ross, G. D. (1996). Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J. Immunol. 156:1235-1246.
38. Tsavaris, N., Kosmas, C., Vadiaka, M., Kanelopoulos, P., Boulamatsis, D. (2002). Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br. J. Cancer. 87:21-27.
39. Usui, T., Iwasaki, Y., Hayashi, K., Mizuno, T., Tanaki, M., Shinkai, K., Arakawa, M. (1981). Antitumor activity of water-soluble beta-D-glucan elaborated by Ganoderma applanatum. Agr. Biol. Chem. 45:323-326.
40. Usui, T., Iwasaki, Y., Mizuno, T., Tanaki, M., Shinkai, K., Arakawa, M. (1983). Isolation and characterization of antitumor active beta-D-glucans from the fruit bodies of Ganoderma applanatum. Carbohyd. Res. 115:273-280.
41. Vickers, A. (2000). Recent advances: complementary medicine. Br. Med. J. 321:683-686.
42. Villegas, F. R., Coca, S., Villarrubia, V. G., Jimenez, R., Chillon, M. J., Jareno, J., Zuil, M., Callol, L. (2002). Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 35:23-28.
43. Wang, S. Y., Hsu, M. L., Hsu, H. C., Tzeng, C. H., Lee, S. S., Shiao, M. S., Ho, C. K. (1997). The anti-tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T lymphocytes. Int. J. Cancer 70:699-705.
44. Wasser, S. P., Weis, A. L. (1999). Therapeutic effects of substances occurring in higher basidiomycetes mushrooms: a modern perspective. Crit. Rev. Immunol. 19:65-96.
45. Werner, G. H., Jolles, P. (1996). Immunostimulating agents - what next - a review of their present and potential medical applications. Eur. J. Biochem. 242:1-19.
46. Zhang, J. S., Tang, Q. J., Zimmerman-Kordmann, M., Reutter, W., Fan, H. (2002). Activation of B lymphocytes by GLIS, a bioactive proteoglycan from Ganoderma lucidum. Life Sci. 71:623-638.
47. Zhou, S. F., Gao, Y. H. (2002). The immunomodulating effects of Ganoderma lucidum (Curt.: Fr) P. Karst (Ling Zhi Reishi mushroom) (Aphyllophoromycetideae). Int. J. Med. Mushroom 4:1-11.
48. Zhou, S. F., Kestell, P., Baguley, B. C., Paxton, J. W. (2002). 5,6-Dimethylxanthenone-4-acetic acid: a novel biological response modifier for cancer therapy. Invest. New Drugs 20:281-295.